92 related articles for article (PubMed ID: 8687125)
1. Chemopreventive activities of C-glucuronide/glycoside analogs of retinoid-O-glucuronides against breast cancer development and growth.
Curley RW; Abou-Issa H; Panigot MJ; Repa JJ; Clagett-Dame M; Alshafie G
Anticancer Res; 1996; 16(2):757-63. PubMed ID: 8687125
[TBL] [Abstract][Full Text] [Related]
2. Chemopreventive activity of a C-glucuronide analog of N-(4-hydroxyphenyl) retinamide-O-glucuronide against mammary tumor development and growth.
Abou-Issa HM; Alshafie GA; Curley RW; Wong MF; Clagett-Dame M; Repa JJ; Sikri V
Anticancer Res; 1999; 19(2A):999-1004. PubMed ID: 10368645
[TBL] [Abstract][Full Text] [Related]
3. In vivo use of N-(4-hydroxyphenyl retinamide)-0-glucuronide as a breast cancer chemopreventive agent.
Abou-Issa H; Curley RW; Panigot MJ; Wilcox KA; Webb TE
Anticancer Res; 1993; 13(5A):1431-6. PubMed ID: 8239515
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic evaluation of N-(4-hydroxyphenyl) retinamide-O-glucuronide in the rat mammary tumor model.
Abou-Issa H; Curley RW; Panigot MJ; Tanagho SN; Sidhu BS; Alshafie GA
Anticancer Res; 1997; 17(5A):3335-9. PubMed ID: 9413168
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HBR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl) retinamide (4-HPR) against mammary carcinogenesis.
Abou-Issa H; Curley RW; Alshafie GA; Weiss KL; Clagett-Dame M; Chapman JS; Mershon SM
Anticancer Res; 2001; 21(6A):3839-44. PubMed ID: 11911255
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and preliminary chemotherapeutic evaluation of the fully C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
Walker JR; Alshafie G; Nieves N; Ahrens J; Clagett-Dame M; Abou-Issa H; Curley RW
Bioorg Med Chem; 2006 May; 14(9):3038-48. PubMed ID: 16412653
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mammary tumor growth by a novel nontoxic retinoid: chemotherapeutic evaluation of a C-linked analog of 4-HPR-glucuronide.
Alshafie GA; Walker JR; Curley RW; Clagett-Dame M; Highland MA; Nieves NJ; Stonerock LA; Abou-Issa H
Anticancer Res; 2005; 25(3c):2391-8. PubMed ID: 16082771
[TBL] [Abstract][Full Text] [Related]
8. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas.
Alshafie GA; Harris RE; Robertson FM; Parrett ML; Ross M; Abou-Issa H
Anticancer Res; 1999; 19(4B):3031-6. PubMed ID: 10652588
[TBL] [Abstract][Full Text] [Related]
9. Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis.
Abou-Issa H; Moeschberger M; el-Masry W; Tejwani S; Curley RW; Webb TE
Anticancer Res; 1995; 15(3):805-10. PubMed ID: 7645962
[TBL] [Abstract][Full Text] [Related]
10. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid.
Udeani GO; Gerhauser C; Thomas CF; Moon RC; Kosmeder JW; Kinghorn AD; Moriarty RM; Pezzuto JM
Cancer Res; 1997 Aug; 57(16):3424-8. PubMed ID: 9270008
[TBL] [Abstract][Full Text] [Related]
11. N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.
Simeone AM; Deng CX; Kelloff GJ; Steele VE; Johnson MM; Tari AM
Carcinogenesis; 2005 May; 26(5):1000-7. PubMed ID: 15695235
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of growth inhibition of mammary carcinomas by glucarate and the glucarate: retinoid combination.
Webb TE; Abou-Issa H; Stromberg PC; Curley RC; Nguyen MH
Anticancer Res; 1993; 13(6A):2095-9. PubMed ID: 8297119
[TBL] [Abstract][Full Text] [Related]
13. Antitumor and chemopreventive effects of a clomiphene analog, MDL 103,323, in mammary carcinoma.
Bitonti AJ; Baumann RJ; Bush TL; Cashman EA; Wright CL; Prakash NJ
Anticancer Res; 1996; 16(5A):2553-7. PubMed ID: 8917350
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.
Ciolino HP; Wang TT; Sathyamoorthy N
Br J Cancer; 2000 Aug; 83(3):333-7. PubMed ID: 10917548
[TBL] [Abstract][Full Text] [Related]
15. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
[TBL] [Abstract][Full Text] [Related]
16. N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells.
Simeone AM; Colella S; Krahe R; Johnson MM; Mora E; Tari AM
Carcinogenesis; 2006 Mar; 27(3):568-77. PubMed ID: 16199439
[TBL] [Abstract][Full Text] [Related]
17. Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms.
Parrett ML; Abou-Issa HM; Alshafie G; Ross MS; Harris RE; Robertson FM
Anticancer Res; 1999; 19(6B):5079-85. PubMed ID: 10697514
[TBL] [Abstract][Full Text] [Related]
18. Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs.
Mershon SM; Anding AL; Chapman JS; Clagett-Dame M; Stonerock LA; Curley RW
Bioorg Med Chem Lett; 2007 Feb; 17(3):836-40. PubMed ID: 17112722
[TBL] [Abstract][Full Text] [Related]
19. Effects of lycopene-enriched tomato oleoresin on 7,12-dimethyl-benz[a]anthracene-induced rat mammary tumors.
Sharoni Y; Giron E; Rise M; Levy J
Cancer Detect Prev; 1997; 21(2):118-23. PubMed ID: 9101071
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.
Gottardis MM; Bischoff ED; Shirley MA; Wagoner MA; Lamph WW; Heyman RA
Cancer Res; 1996 Dec; 56(24):5566-70. PubMed ID: 8971154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
